
Biospectal is a Swiss-based medical technology company pioneering mobile remote patient monitoring with its AI-driven OptiBP smartphone app, the first and only CE-MDR EU Class IIa certified and clinically validated blood pressure monitor app worldwide. The app uses a smartphone camera and fingertip to measure blood pressure quickly and comfortably without a cuff, enabling users to track and share their blood pressure data for better heart health management. Biospectal operates a subscription business model with weekly and yearly plans, targeting consumers and healthcare delivery systems globally. The company is headquartered in Lausanne, Switzerland, and has a multinational team with expertise in medical, software, and machine learning fields. Biospectal has received media coverage in major outlets and is recognized for innovation in digital health and biosensing software.

Biospectal is a Swiss-based medical technology company pioneering mobile remote patient monitoring with its AI-driven OptiBP smartphone app, the first and only CE-MDR EU Class IIa certified and clinically validated blood pressure monitor app worldwide. The app uses a smartphone camera and fingertip to measure blood pressure quickly and comfortably without a cuff, enabling users to track and share their blood pressure data for better heart health management. Biospectal operates a subscription business model with weekly and yearly plans, targeting consumers and healthcare delivery systems globally. The company is headquartered in Lausanne, Switzerland, and has a multinational team with expertise in medical, software, and machine learning fields. Biospectal has received media coverage in major outlets and is recognized for innovation in digital health and biosensing software.
Product: OptiBP — AI-driven smartphone app for cuffless blood pressure measurement using fingertip and phone camera
Regulatory status: CE MDR Class IIa certified
Founded: July 2017
Headquarters: Lausanne, Switzerland
Latest disclosed funding: Seed round July 2021 (CHF 4.0M / ~USD 4.3M)
Remote patient monitoring, cardiovascular health management, non-invasive biosensing
2017
Digital health / Medical software
CHF 4.0M (~USD 4.3M)
Additional participants included LabCorp, Athensmed, Privilège Ventures and other investors